公开(公告)号：US11142525B2

公开(公告)日：2021-10-12

申请号：US16679820

申请日：2019-11-11

申请人： Pfizer Inc.

发明人： Rebecca Anne Gallego ,  Sajiv Krishnan Nair ,  Robert Steven Kania ,  Omar Khaled Ahmad ,  Ted William Johnson ,  Jamison Bryce Tuttle ,  Mehran Jalaie ,  Michele Ann McTigue ,  Dahui Zhou ,  Matthew L. Del Bel ,  Ru Zhou ,  Mingying He ,  Anne-Marie Dechert Schmitt

IPC分类号： C07D471/04 ,  A61P35/00

摘要： This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11993625B2

公开(公告)日：2024-05-28

申请号：US16477290

申请日：2018-01-10

申请人： PFIZER INC.

发明人： Omar Khaled Ahmad ,  Stephen Paul Brown ,  Kenneth John Dirico ,  Russell Dushin ,  Gary Frederick Filzen ,  Sujiet Puthenveetil ,  Pavel Strop ,  Chakrapani Subramanyam ,  Lawrence N. Tumey

IPC分类号： C07H15/26 ,  A61K47/68 ,  A61P35/00 ,  A61K45/06

CPC分类号： C07H15/26 ,  A61K47/6807 ,  A61P35/00 ,  A61K45/06

摘要： The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.

公开(公告)号：US20200172539A1

公开(公告)日：2020-06-04

申请号：US16679820

申请日：2019-11-11

申请人： Pfizer Inc.

发明人： Rebecca Anne Gallego ,  Sajiv Krishnan Nair ,  Robert Steven Kania ,  Omar Khaled Ahmad ,  Ted William Johnson ,  Jamison Bryce Tuttle ,  Mehran Jalaie ,  Michele Ann McTigue ,  Dahui Zhou ,  Matthew L. Del Bel ,  Ru Zhou ,  Mingying He

IPC分类号： C07D471/04 ,  A61P35/00

摘要： This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.